Pharmaceuticals, Biotechnology and Life Sciences
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of…
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology…
This investment, led by Founders Fund with participation from Lux Capital and Field Ventures, brings total investment to date to…
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response…
Semnur’s shares of common stock and warrants are expected to continue to trade on the OTC Markets under the ticker…
EDMONTON, Alberta and CALGARY, Alberta, Sept. 22, 2025 (GLOBE NEWSWIRE) — This morning, at events in Edmonton and Calgary, Applied…
Change in General Management Villepinte France, September 22nd, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions…
Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with…
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS…
Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with…